Precigen, Inc.
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Intrexon Corporation (to 2020)
0
Ending by 2030
Jun 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Modulating Expression of Polypeptides via New Gene Switch Expression Systems (US 11,692,194) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 2 fees due Apr 3 to 17, 2027 · next Apr 3
- 1 fee due Oct 2, 2027The maintenance fee for Modulating Expression of Polypeptides via New Gene Switch Expression Systems (US 11,946,054) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
- Nov 10 US 12,790,408 MUC16 Specific Chimeric Antigen Receptors and Uses Thereof
- Oct 13 US 12,760,083 Chimeric Receptor Therapy
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,559,536 | CD33 Specific Chimeric Antigen Receptors In force · High confidence | In force | High confidence | |
| US 11,692,194 | Modulating Expression of Polypeptides via New Gene Switch Expression Systems In force · High confidence | In force | High confidence | |
| US 11,118,168 | Expression of Novel Cell Tags In force · High confidence | In force | High confidence | |
| US 11,116,852 | Frataxin Expression Constructs In force · High confidence | In force | High confidence | |
| US 11,608,362 | Hepatitis B Vaccines and Uses of the Same In force · High confidence | In force | High confidence | |
| US 12,234,261 | Hepatitis B Vaccines and Uses of the Same In force · High confidence | In force | High confidence | |
| US 12,180,517 | Expression of Novel Cell Tags In force · High confidence | In force | High confidence | |
| US 11,319,380 | MUC16 Specific Chimeric Antigen Receptors and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,976,134 | MUC16 Specific Chimeric Antigen Receptors and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,981,746 | MUC16 Specific Chimeric Antigen Receptors and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 23: 18 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 1 abandoned · 4 no status recorded
Showing 1 to 10 of 16, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/023,657 | Hepatitis B Vaccines and Uses of the Same | Jan 16, 2025 | Pending |
| 18/966,676 | Fusion Constructs and Methods of Using Thereof | Dec 3, 2024 | Pending |
| 18/953,059 | Expression of Novel Cell Tags | Nov 20, 2024 | Pending |
| 18/805,099 | Molecular Switches | Aug 14, 2024 | Pending |
| 18/671,685 | Novel Adenovirus Vaccine Therapy for the Treatment of Recurrent Respiratory Papillomatosis | May 22, 2024 | Pending |
| 18/671,275 | Human Papillomavirus Vaccines and Uses of the Same | May 22, 2024 | Pending |
| 18/661,283 | Methods and Microorganisms for Making 1,4-Butanediol and Derivatives Thereof from C1 Carbons | May 10, 2024 | Pending |
| 18/426,680 | Method for Integration of Transgenes | Jan 30, 2024 | Pending |
| 18/485,838 | Oct 12, 2023 | No status recorded | |
| 18/357,565 | Frataxin Expression Constructs | Jul 24, 2023 | Abandoned |
10 of 16 applications shown.
Pro members see all 16 published applications.